Skip to main content
SpringerLink
Log in

Beclometasone Dipropionate/Formoterol

In an HFA-Propelled Pressurised Metered-Dose Inhaler

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ A hydrofluoroalkane (HFA)-propelled pressurised metered-dose inhaler (pMDI) has been developed (using Modulite® technology) for a new fixed combination of beclometasone dipropionate/formoterol fumarate (BDP/formoterol) 100μg/6μg. Each actuation of the BDP/formoterol HFA pMDI 100μg/6μg delivers 86.4μg of BDP and 5μg of formoterol.

  • ▴ BDP/formoterol HFA pMDI was associated with significantly higher morning peak expiratory flow (PEF) values than BDP administered alone via a chlorofluorocarbon (CFC) pMDI (including when BDP was administered at a higher dosage) in well designed trials in adults with mild to moderate or moderate to severe asthma.

  • ▴ In terms of morning PEF values, BDP/formoterol HFA pMDI was noninferior to BDP plus formoterol administered via separate inhalers in well designed trials in adults with moderate to severe asthma.

  • ▴ BDP/formoterol HFA pMDI was noninferior to fixed-combination budesonide/formoterol (the daily dosage of BDP was half that of budesonide) in terms of lung function, asthma symptoms and use of rescue medications in adults with moderate to severe asthma. BDP/formoterol HFA pMDI was also noninferior to, and had a faster onset of bronchodilation than, fixed-combination fluticasone propionate/salmeterol.

  • ▴ BDP/formoterol 200μg/12μg per day or 400μg/ 24μg per day administered by the HFA pMDI was generally well tolerated. Moreover, a single high dose of BDP/formoterol (1000μg/60μg) was generally well tolerated in patients with asthma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification only and does not imply endorsement.

References

  1. Global Initiative for Asthma. Global strategy for asthma management and prevention [online]. Available from URL: http://www.ginasthma.org [Accessed 2005 Oct 17]

  2. British Thoracic Society. British guideline on the management of asthma: a national clinical guideline [online]. Available from URL: http://www.sign.ac.uk/pdf/sign63.pdf [Accessed 2005 Jun 15]

  3. National Institutes of Health. Pharmacologic therapy: the medications. In: Guidelines for the diagnosis and management of asthma [NIH Publication No. 97-4051]: Bethesda (MD), 1997: 59-79

  4. Roche N, Morel H, Martel P, et al. Clinical practice guidelines: medical follow-up of patients with asthma-adults and adolescents. Respir Med 2005; 99(7): 793–815

    Article  PubMed  Google Scholar 

  5. Mitchell C, Jenkins C, Scicchitano R, et al. Formoterol (Foradil) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma. Pulm Pharmacol Ther 2003; 16: 299–306

    Article  PubMed  CAS  Google Scholar 

  6. Bouros D, Bachlitzanakis N, Kottakis J, et al. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. Eur Respir J 1999; 14: 627–32

    Article  PubMed  CAS  Google Scholar 

  7. Bousquet J. Introduction. Modulite®: simplifying the changeover. Respir Med 2002 Aug; 96 Suppl. D: S1–2

    Article  PubMed  Google Scholar 

  8. Chiesi Farmaceutici SpA. Modulite®: the value of Chiesi’s technology in the treatment of asthma and COPD [online]. Available from URL: http://www.chiesigroup.com [Accessed 2006 May 25]

  9. Poli G, Acerbi D, Brand P, et al. Lung deposition of formoterol HFA in healthy volunteers, asthmatic and COPD patients [abstract No. P2077 plus poster]. Eur Respir J 2005; 26 (Suppl. 49): 314

    Google Scholar 

  10. Lewis D, Brambilla G, Church T, et al. BDP and formoterol association within a combination HFA solution MDI. Respiratory Drug Delivery X 2006; 3: 939–42

    Google Scholar 

  11. Data on file. Chiesi Farmaceutici, 2005

  12. Ganderton D, Lewis D, Davies R, et al. Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med 2002; 96 (Supl D): S3–8

    Article  PubMed  Google Scholar 

  13. Acerbi D, Brambilla G, Kottakis I. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology. Pulm Pharmacol Ther 2006. Epublication ahead of print: doi:10.1016/j.pupt.2006.05.005

  14. Woodcock A, Acerbi D, Poli G. Modulite technology: pharmacodynamic and pharmacokinetic implications. Respir Med 2002; 96 (Suppl D): S9–15

    Article  PubMed  Google Scholar 

  15. Brambilla G, Gaderton D, Garzia R, et al. Modulation of aerosol clouds produced by pressurised inhalation aerosols. Int J Pharm 1999; 186: 53–61

    Article  PubMed  CAS  Google Scholar 

  16. Lewis DA, Ganderton D, Meakin BJ, et al. Theory and practice with solution systems. Respiratory Drug Delivery IX 2004; 1: 109–16

    Google Scholar 

  17. Nelson HS, Chapman KR, Pyke SD, et al. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 2003; 112(1): 29–36

    Article  PubMed  CAS  Google Scholar 

  18. van Schayck CP, Donnell D. The efficacy and safety of QVAR (hydrofluoroalkane-beclometasone dipropionate extrafine aerosol) in asthma (part 1): an update of clinical experience in adults. Int J Clin Pract 2004; 58(7): 678–88

    Article  PubMed  Google Scholar 

  19. Rigamonti E, Kottakis I, Pelc M, et al. Comparison of a new HFA134a-formulated extra-fine beclometasone dipropionate pMDI with a standard CFC-formulated BDP pMDI in adults with moderate persistent asthma [abstract]. 16th Annual Congress of the European Respiratory Society; 2006 Sep 2–6; Munich

  20. Poli G, Acerbi D, Nollevaux F. Pharmacokinetics and pharmacodynamics of a new beclomethasone dipropionate and formoterol CFC-free fixed combination in healthy volunteers [abstract]. 16th Annual Congress of the European Respiratory Society; 2006 Sep 2–6; Munich

  21. Chung KF, Adcock IM. Combination therapy of long-acting beta-2-adrenoceptor agonists and corticosteroids for asthma. Treat Respir Med 2004; 3(5): 279–89

    Article  PubMed  CAS  Google Scholar 

  22. Derom E, Pauwels RA. Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices. Clin Pharmacokinet 2005; 44(8): 815–36

    Article  PubMed  CAS  Google Scholar 

  23. Biggadike K, Uings I, Farrow SN. Designing corticosteroid drugs for pulmonary selectivity. Proc Am Thorac Soc 2004; 1: 352–5

    Article  PubMed  CAS  Google Scholar 

  24. Cheer SM, Scott LJ. Formoterol: a review of its use in chronic obstructive pulmonary disease. Am J Respir Med 2002; 1(4): 285–300

    Article  PubMed  CAS  Google Scholar 

  25. Lötvall J. Pharmacological similarities and differences between β2-agonists. Respir Med 2001; 95 Suppl. B: S7–11

    Article  PubMed  Google Scholar 

  26. Palmqvist M, Persson G, Lazer L, et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10: 2484–9

    Article  PubMed  CAS  Google Scholar 

  27. Rabe KF, Jorres R, Nowak D, et al. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma. Am Rev Respir Dis 1993; 147: 1436–41

    PubMed  CAS  Google Scholar 

  28. Profita M, Gagliardo R, Di Giorgi R, et al. Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics. Allergy 2005; 60(3): 323–9

    Article  PubMed  CAS  Google Scholar 

  29. Eickelberg O, Roth M, Lorx R, et al. Ligand-independent activation of the glucocorticoid receptor by β2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999; 274(2): 1005–10

    Article  PubMed  CAS  Google Scholar 

  30. Pang L, Knox AJ. Synergistic inhibition of β2-agonists and corticosteroids on tumor necrosis factor-a-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am J Resp Cell Mol Biol 2000; 23: 79–85

    CAS  Google Scholar 

  31. Piccinno A, Borrill Z, Poli G, et al. Tolerability of high cumulative doses of a new fixed combination of beclomethasone dipropionate/formoterol in asthmatic patients. 16th Annual Congress of the European Respiratory Society; 2006 Sep 2–6; Munich

  32. Daley-Yates PT, Price AC, Sisson JR, et al. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001; 51: 400–9

    Article  PubMed  CAS  Google Scholar 

  33. Bonnet-Gonod F, Kottakis I, Ballabio M, et al. Superior efficacy of a low daily dose of a new fixed combination of beclometasone dipropionate/formoterol pMDI compared to an increased daily dose of BDP in moderate persistent asthma: a 3 month clinical study [abstract]. 16th Annual Congress of the European Respiratory Society; 2006 Sep 2–6; Munich

  34. Paggiaro P, Papi A, Feschenko YI, et al. Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma [abstract]. 16th Annual Congress of the European Respiratory Society; 2006 Sep 2–6; Munich

  35. Papi A, Paggiaro P, Zarkovic J, et al. Efficacy and safety of the new beclomethasone dipropionate/formoterol combination (HFA MDI) vs. budesonide/formoterol (DPI) in moderate to severe persistent asthma [abstract]. 16th Annual Congress of the European Respiratory Society; 2006 Sep 2–6; Munich

  36. Bonnet-Gonod F, Kottakis I, Hofman T, et al. Beclometasone dipropionate/formoterol in a single inhaler improves lung function and clinically meaningful outcomes in moderate to severe asthma [abstract]. 16th Annual Congress of the European Respiratory Society; 2006 Sep 2–6; Munich

  37. Ankerst J, Persson G, Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulm Pharmacol Ther 2003; 16: 147–51

    Article  PubMed  CAS  Google Scholar 

  38. Chiesi Farmaceutici SpA. Wortlaut der fur das Behaltnis (Druckbehaltnis) vogesehenen Angaben: SmPC Foster 100/6 Mikrogramm. Italy: Chiesi Farmaceutici SpA, July 2006

    Google Scholar 

  39. Bundesinstitut fur Arzneimittel und Medizinprodukte. Approval letter for Kantos 100/6 Mikrogramm Druckgasinhalation and Foster 100/6 Mikrogramm Druckgasinhalation. 2006 Jul 14

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Sohita Dhillon & Gillian M. Keating

Authors
  1. Sohita Dhillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sohita Dhillon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dhillon, S., Keating, G.M. Beclometasone Dipropionate/Formoterol. Drugs 66, 1475–1483 (2006). https://doi.org/10.2165/00003495-200666110-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666110-00005

Keywords

Search

Navigation